---
layout: post
title: New Drug Approvals 2014 - Pt. XII - Naloxegol (Movantikâ„¢)
date: '2014-10-16T09:45:00.001+01:00'
author: Louisa
tags:
- Oral Drugs
- Small Molecule Drugs
- 2014 New Drugs
modified_time: '2014-10-16T09:45:50.332+01:00'
thumbnail: http://4.bp.blogspot.com/-wSK5v0omCgU/VD6F8GFuqCI/AAAAAAAAANY/jeMTRpG5A6E/s72-c/movantik_us_cii_tm_5c.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-6228467327043268475
blogger_orig_url: http://chembl.blogspot.com/2014/10/new-drug-approvals-2014-pt-xii.html
---

<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-wSK5v0omCgU/VD6F8GFuqCI/AAAAAAAAANY/jeMTRpG5A6E/s1600/movantik_us_cii_tm_5c.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://4.bp.blogspot.com/-wSK5v0omCgU/VD6F8GFuqCI/AAAAAAAAANY/jeMTRpG5A6E/s1600/movantik_us_cii_tm_5c.jpg" height="97" width="320" /></a></div>
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-hwSSs4HQ27E/VD6Hh7AfU6I/AAAAAAAAANs/AFUmaKAPe08/s1600/drugicon.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img alt="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,0,0,1,0,1,0,0,0,1" border="0" src="http://2.bp.blogspot.com/-hwSSs4HQ27E/VD6Hh7AfU6I/AAAAAAAAANs/AFUmaKAPe08/s1600/drugicon.jpg" height="33" title="" width="320" /></a></div>
<br />
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>ATC Code: </b><a href="http://en.wikipedia.org/wiki/ATC_code_A06AH" target="_blank">A06AH03</a></span></div>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>Wikipedia:&nbsp;</b><a href="http://en.wikipedia.org/wiki/Naloxegol" target="_blank">Naloxegol</a></span></div>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>ChEMBL:&nbsp;</b><a href="https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2219418" target="_blank">CHEMBL2219418</a></span></div>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><br /></span></div>
<span style="font-family: Verdana, sans-serif;">On September 16th&nbsp;<a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm414620.htm" target="_blank">FDA approved</a>&nbsp;Movantik (naloxegol, AZ-13337019</span><span style="font-family: Verdana, sans-serif;">), as an oral treatment for patients with opioid-induced constipation and chronic non-cancer pain.</span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;"><b>Naloxegol</b></span><br />
<span style="font-family: Verdana, sans-serif;">Naloxegol is an <a href="http://en.wikipedia.org/wiki/Opioid_antagonist" target="_blank">opioid receptor antagonist</a>.&nbsp;</span><span style="font-family: Verdana, sans-serif;">Due to its similarity to noroxymorphone, a main metabolite of </span><a href="http://en.wikipedia.org/wiki/Oxycodone" style="font-family: Verdana, sans-serif;" target="_blank">oxycodone</a><span style="font-family: Verdana, sans-serif;">, naloxegol is classed as a controlled substance. However, the FDA analysed its abuse potential and concluded that there was no risk of dependency.</span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<br />
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="http://3.bp.blogspot.com/-4TE3VZQxK8w/VD6LJ3AxrXI/AAAAAAAAAN4/Qucoq5e44O0/s1600/naloxegol.jpg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" src="http://3.bp.blogspot.com/-4TE3VZQxK8w/VD6LJ3AxrXI/AAAAAAAAAN4/Qucoq5e44O0/s1600/naloxegol.jpg" height="203" width="400" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-family: Verdana, sans-serif;">Naloxegol</span></td></tr>
</tbody></table>
<span style="font-family: Verdana, sans-serif;"><b><br /></b></span>
<span style="font-family: Verdana, sans-serif;"><br /></span>
<br />
<div>
<span style="font-family: Verdana, sans-serif;"><b>Mode of Action</b></span></div>
<div>
<span style="font-family: Verdana, sans-serif;"><a href="http://en.wikipedia.org/wiki/Opioid" target="_blank">Opioids</a> are a class of drugs which are used to manage pain, but have a common side effect of reducing the motility of the gastrointestinal tract, making bowel movements difficult.&nbsp;</span><span style="font-family: Verdana, sans-serif;">Opioids work by binding to the mu-receptors (<a href="https://www.ebi.ac.uk/chembl/target/inspect/CHEMBL233" target="_blank">CHEMBL233</a>, <a href="http://www.uniprot.org/uniprot/P35372" target="_blank">UniProt:P35372</a>) in the central nervous system, thereby reducing pain. However, they are also able to bind to the mu-receptors in the gastrointestinal tract, hence causing opioid-induced constipation.&nbsp;</span><br />
<span style="font-family: Verdana, sans-serif;">Movantik is a peripherally-acting opioid receptor antagonist, which is able to prevent </span><a href="http://en.wikipedia.org/wiki/Constipation" style="font-family: Verdana, sans-serif;" target="_blank">constipation</a><span style="font-family: Verdana, sans-serif;"> by reducing this specific side effect of the opioids without affecting the efficacy of the pain management.</span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;"><b>Clinical Trials</b></span><br />
<span style="font-family: Verdana, sans-serif;">The clinical trials for this drug were carried out on a KODIAC clinical programme, comprising of four studies. Tests showed that 44% and 41% of patients receiving 25mg and 12.5mg, respectively, experienced increased bowel movements, compared to just 29% who took the placebo.<a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1310246" target="_blank"> [Paper]</a></span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<br />
<div>
<span style="font-family: Verdana, sans-serif;"><b>Indication and Warnings</b></span></div>
<div>
<span style="font-family: Verdana, sans-serif;">This drug is for non-cancer related pain. Side effects have been abdominal pain, diarrhea, headache and excessive gas in the stomach and/or intestinal area.&nbsp;</span><br />
<span style="font-family: Verdana, sans-serif;">When used in conjunction with another peripherally-acting opioid antagonist, there is the chance of gastrointestinal perforation.</span><br />
<span style="font-family: Verdana, sans-serif;">There is also the chance of withdrawal symptoms.</span><br />
<span style="font-family: Verdana, sans-serif;">This is contraindicated for anyone who is also taking CYP3A4 (<a href="https://www.ebi.ac.uk/chembl/target/inspect/CHEMBL5792" target="_blank">CHEMBL5792</a>, <a href="http://www.uniprot.org/uniprot/Q9HB55" target="_blank">UniProt:Q9HB55</a>) inhibitors, such as clarithromycin (<a href="https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1741" target="_blank">CHEMBL1741</a>), as this will increase the exposure to naloxegol and could precipitate opioid withdrawal symptoms.&nbsp;</span><span style="font-family: Verdana, sans-serif;"><a href="http://www.azpicentral.com/movantik/movantik.pdf" target="_blank">[FDA]</a></span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;"><b>Trade Names</b></span><br />
<span style="font-family: Verdana, sans-serif;">Naloxegol was developed by AstraZeneca and is marketed under the trade name of Movantik. It is due for release during the first quarter of 2015.</span></div>
</div>
